benserazide has been researched along with Cognitive Dysfunction in 2 studies
Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.
Cognitive Dysfunction: Diminished or impaired mental and/or intellectual function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The prevention and treatment of sepsis associated encephalopathy (SAE) remains challenging in clinic." | 5.56 | Small dose of L-dopa/Benserazide hydrochloride improved sepsis-induced neuroinflammation and long-term cognitive dysfunction in sepsis mice. ( Chen, S; Duan, S; Fang, J; Le, Y; Li, D; Li, F; Qing, W; Tan, L; Tong, J; Wang, Y; Yang, J; Zhang, B, 2020) |
| "The prevention and treatment of sepsis associated encephalopathy (SAE) remains challenging in clinic." | 1.56 | Small dose of L-dopa/Benserazide hydrochloride improved sepsis-induced neuroinflammation and long-term cognitive dysfunction in sepsis mice. ( Chen, S; Duan, S; Fang, J; Le, Y; Li, D; Li, F; Qing, W; Tan, L; Tong, J; Wang, Y; Yang, J; Zhang, B, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Che, NN | 1 |
| Chen, SY | 1 |
| Li, X | 1 |
| Ma, JJ | 1 |
| Yang, HQ | 1 |
| Li, F | 1 |
| Zhang, B | 1 |
| Duan, S | 1 |
| Qing, W | 1 |
| Tan, L | 1 |
| Chen, S | 1 |
| Wang, Y | 1 |
| Li, D | 1 |
| Yang, J | 1 |
| Tong, J | 1 |
| Fang, J | 1 |
| Le, Y | 1 |
2 other studies available for benserazide and Cognitive Dysfunction
| Article | Year |
|---|---|
Autoimmune-mediated secondary-parkinsonism presented with micrographia and cognitive impairment.
Topics: Adult; Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Antiparkinson Agents; Autoantibodies; Benser | 2021 |
Small dose of L-dopa/Benserazide hydrochloride improved sepsis-induced neuroinflammation and long-term cognitive dysfunction in sepsis mice.
Topics: Animals; Benserazide; Brain; Cognitive Dysfunction; Disease Models, Animal; Drug Combinations; Hippo | 2020 |